The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Open accessAbstract
Motivation: Many drug combinations are routinely assessed to identify synergistic interactions in the attempt to develop novel treatment strategies. Appropriate software is required to analyze the results of these studies. Results: We present Combenefit, new free software tool that enables the visualization, analysis and quantification of drug combination effects in terms of synergy and/or antagonism. Data from combinations assays can be processed using classical Synergy models (Loewe, Bliss, HSA), as single experiments or in batch for High Throughput Screens. This user-friendly tool provides laboratory scientists with an easy and systematic way to analyze their data. The companion package provides bioinformaticians with critical implementations of routines enabling the processing of combination data. Availability and Implementation: Combenefit is provided as a Matlab package but also as standalone software for Windows (http://sourceforge.net/projects/combenefit/). Contact: Giovanni.DiVeroli@cruk.cam.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Synergy, antagonism, and what the chequerboard puts between them
Odds, F. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg301 · Cited by 2,481
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
(1953) · PubMed · Cited by 942
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Über Kombinationswirkungen: Mitteilung: Hilfsmittel der Fragestellung
Loewe, S., & Muischnek, H. (1926) · Archiv für Experimentelle Pathologie und Pharmakologie · doi:10.1007/bf01952257 · Cited by 760
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Loewe, S., Käer, E., & Muischnek, H. (1927) · Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie · doi:10.1007/bf01859944 · Cited by 538
Mathews Griner, L. A., Guha, R., Shinn, P., Young, R. M., Keller, J. M., Liu, D., Goldlust, I. S., Yasgar, A., McKnight, C., Boxer, M. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311846111 · Cited by 377
Research works printed but not linked: 1
- Webb, 1963, Effect of more than one inhibitor, Enzyme Metab. Inhib, 1, 66
Cited by
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Ianevski, A., Giri, A. K., & Aittokallio, T. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac382 · Cited by 778
Zheng, S., Wang, W., Aldahdooh, J., Malyutina, A., Shadbahr, T., Tanoli, Z., Pessia, A., & Tang, J. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.01.004 · Cited by 733
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653
Kinsey, C. G., Camolotto, S. A., Boespflug, A. M., Guillen, K. P., Foth, M., Truong, A., Schuman, S. S., Shea, J. E., Seipp, M. T., Yap, J. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0367-9 · Cited by 634
Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 555
SynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T., & Tang, J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 530
Guillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C.-H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00337-6 · Cited by 416
Menden, M. P., Wang, D., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T., Kang, J., Jeon, M., Wolfinger, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 363
Self-citationDuarte, D., & Vale, N. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100110 · Cited by 340
DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
Wang, J., Liu, X., Shen, S., Deng, L., & Liu, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab390 · Cited by 261
Looking beyond the hype: applied AI and machine learning in translational medicine
Toh, T. S., Dondelinger, F., & Wang, D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.027 · Cited by 159
Self-citationCediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4508 · Cited by 158
Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0253 · Cited by 130
Pal, S., Kozono, D., Yang, X., Fendler, W., Fitts, W., Ni, J., Alberta, J. A., Zhao, J., Liu, K. X., Bian, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3691 · Cited by 101
Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
Gulay, K. C. M., Zhang, X., Pantazopoulou, V., Patel, J., Esparza, E., Pran Babu, D. S., Ogawa, S., Weitz, J., Ng, I., Mose, E. S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1313 · Cited by 89
Additive dose response models: defining synergy
Lederer, S., Dijkstra, T. M. H., & Heskes, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01384 · Cited by 74
DTSyn: a dual-transformer-based neural network to predict synergistic drug combinations
Hu, J., Gao, J., Fang, X., Liu, Z., Wang, F., Huang, W., Wu, H., & Zhao, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac302 · Cited by 65
Zhou, Z.-W., Ambrogio, C., Bera, A. K., Li, Q., Li, X.-X., Li, L., Son, J., Gondi, S., Li, J., Campbell, E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0448 · Cited by 60
Schultz, C. W., McCarthy, G. A., Nerwal, T., Nevler, A., DuHadaway, J. B., McCoy, M. D., Jiang, W., Brown, S. Z., Goetz, A., Jain, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0652 · Cited by 34
Self-citationLi, H., Liu, S., Jin, R., Xu, H., Li, Y., Chen, Y., & Zhao, G. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00654-2 · Cited by 34
Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models
Mao, B., & Guo, S. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0243 · Cited by 27
Kortüm, B., Radhakrishnan, H., Zincke, F., Sachse, C., Burock, S., Keilholz, U., Dahlmann, M., Walther, W., Dittmar, G., Kobelt, D., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02407-6 · Cited by 26
Gmeiner, W. H., Dominijanni, A., Haber, A. O., Ghiraldeli, L. P., Caudell, D. L., D’Agostino, R., Pasche, B. C., Smith, T. L., Deng, Z., Kiren, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0516 · Cited by 21
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
Huang, L., Wang, J., Fang, B., Meric-Bernstam, F., Roth, J. A., & Ha, M. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-16933-6 · Cited by 21
Dasilva, M. A., Andrada, K. F. C., Torales, M. M., Hughes, I. M., Pez, P., García-Martínez, J. C., & Paraje, M. G. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02415-6 · Cited by 16
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
Sun, K., Jin, L., Karolová, J., Vorwerk, J., Hailfinger, S., Opalka, B., Zapukhlyak, M., Lenz, G., & Khandanpour, C. (2023) · Cancers · doi:10.3390/cancers15082373 · Cited by 9
Prediction and identification of synergistic compound combinations against pancreatic cancer cells
KalantarMotamedi, Y., Choi, R. J., Koh, S.-B., Bramhall, J. L., Fan, T.-P., & Bender, A. (2021) · iScience · doi:10.1016/j.isci.2021.103080 · Cited by 8
Self-citationSerala, K., Bai, J., & Prince, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70222 · Cited by 6
Metadata
- Authors
- Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I.
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-04-25
- Volume
- 32
- Issue
- 18
- Pages
- 2866-2868
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- OpenAlex
- W2344726805
- Cited by
- 736
- References
- 19
- FWCI
- 27.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.